Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – ...

First-in-class therapy targets 'undruggable' protein in hard-to-treat blood cancers

A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise ...
RAPS

Study: China outpaces the US in cancer approvals, lags behind on first approvals

While China's National Medical Products Administration (NMPA) approved more oncology drugs compared to the US Food and Drug Administration (FDA) from 2020 to 2025, the US regulator approved more first ...
ascopubs.org

Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study

Low-Dose Total Skin Electron Beam Radiotherapy in Stage IB-IIB Mycosis Fungoides: Results From the Prospective S-MISR Study Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may ...
ascopubs.org

A phase 1 first-in-human study of the novel anti-LLT1 antibody (ZM008) alone and in combination with anti-PD1 antibody in patients with advanced solid tumors.

Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy ...
Business Wire

Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD

SAN FRANCISCO--(BUSINESS WIRE)--Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing first-in-human, open-label study ...